Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Callan Family Office LLC

Callan Family Office LLC decreased its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 58.1% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 2,445 shares of the specialty pharmaceutical company’s stock after selling 3,388 shares during the quarter. Callan Family Office LLC’s holdings in Jazz Pharmaceuticals were worth $322,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Kennedy Capital Management LLC acquired a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at about $1,100,000. Wedge Capital Management L L P NC acquired a new stake in Jazz Pharmaceuticals during the 3rd quarter valued at approximately $27,834,000. Sequoia Financial Advisors LLC purchased a new stake in Jazz Pharmaceuticals during the 3rd quarter worth approximately $605,000. Measured Wealth Private Client Group LLC raised its position in shares of Jazz Pharmaceuticals by 47.1% in the 2nd quarter. Measured Wealth Private Client Group LLC now owns 4,855 shares of the specialty pharmaceutical company’s stock valued at $515,000 after purchasing an additional 1,554 shares in the last quarter. Finally, Schroder Investment Management Group raised its position in shares of Jazz Pharmaceuticals by 90.1% in the 2nd quarter. Schroder Investment Management Group now owns 17,816 shares of the specialty pharmaceutical company’s stock valued at $1,891,000 after purchasing an additional 8,444 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ opened at $165.50 on Friday. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09. The firm’s 50-day moving average price is $167.86 and its two-hundred day moving average price is $145.52. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $182.99. The stock has a market capitalization of $10.06 billion, a P/E ratio of -27.27, a P/E/G ratio of 0.89 and a beta of 0.26.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on JAZZ. Bank of America lifted their price target on shares of Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. JPMorgan Chase & Co. dropped their target price on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research report on Monday, October 27th. Truist Financial increased their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Morgan Stanley reaffirmed an “overweight” rating and set a $225.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, January 8th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Monday, December 29th. Fourteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $205.67.

Insiders Place Their Bets

In related news, Director Heather Ann Mcsharry sold 3,415 shares of the business’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $177.78, for a total transaction of $607,118.70. Following the completion of the transaction, the director owned 20,449 shares in the company, valued at $3,635,423.22. The trade was a 14.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the company’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $169.51, for a total value of $379,363.38. Following the transaction, the senior vice president owned 19,508 shares of the company’s stock, valued at approximately $3,306,801.08. The trade was a 10.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 123,791 shares of company stock worth $21,991,850. 4.30% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.